Clinical trials
Hepatitis D, Chronic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
35 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Recruiting | 6 |
| Active, not recruiting | 6 |
| Unknown status | 4 |
| Withdrawn | 2 |
| Terminated | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 4 |
| Vir Biotechnology, Inc. | 4 |
| Gilead Sciences | 3 |
| EIT Pharma, Inc. | 2 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2 |
| Shanghai HEP Pharmaceutical Co., Ltd. | 2 |
| ANRS, Emerging Infectious Diseases | 1 |
| Aarhus University Hospital | 1 |
| Aga Khan University | 1 |
| Center of target therapy | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hepatitis D, Chronic | 35 |
| Hepatitis D | 10 |
| Hepatitis B, Chronic | 5 |
| Hepatitis | 4 |
| Hepatitis B | 3 |
| Digestive System Diseases | 2 |
| Liver Diseases | 2 |
| Carcinoma, Hepatocellular | 1 |
| Fibrosis | 1 |
| Glomerulonephritis | 1 |
Trials
Showing 26 to 35 of 35. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.